At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 43 enrolled
Drug / intervention
Brimonidine tartrate ophthalmic solution 0.025% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Palpebral Fissure Height
In Brief
A Phase 4 clinical trial evaluating Brimonidine tartrate ophthalmic solution 0.025% and Sterile balanced saline solution for Eyelid Droop. Completed, enrolled 43 participants across 1 site.
Detailed Summary
The purpose of the research is to see if Lumify™ has an effect on eyelid position.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyelid Droop
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJun 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedDec 20, 2018
Enrollment StartJun 18, 2019
Primary CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.5 years ago
Interventions
Brimonidine tartrate ophthalmic solution 0.025%drug
One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
Sterile balanced saline solutionother
One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)